AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Minerva S.A.
Video analysis: MRVSY
All videosNo video analysis for this stock yet. Request one from our team.
News: MRVSY
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that management will participate in two upcoming investor conferences.
MINERVA FOODS REPORTS RECORD NET REVENUE OF R$ 57,2 BILLION FOR THE PAST 12 MONTHS
EBITDA totaled R$ 1.2 billion in 2Q26, with an EBITDA margin of 8.7%. Over the last 12 months, EBITDA totaled R$ 4.9 billion, up 22.1%, with an EBITDA margin of 8.6% SÃO PAULO, Aug. 12, 2026 /PRNewswire/ -- Minerva S.A.
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027 Scientific Advisory Board of leading experts in psychiatry and neuroscience established to guide the confirmatory Phase 3 trial of roluperidone Roluperidone remains the only late-stage drug candidate for this high-need population BURLINGTON, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported financial and business updates for the second quarter ended June 30, 2026.
